By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) – GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Fury Gold resumes drilling at Quebec's project after wildfire halt
July 27 (Reuters) - Fury Gold Mines said on Monday that exploration and drilling activities…
Customer data from India's Bank of Baroda leaked online, source and researcher say
By Gopika Gopakumar and Ashwin Manikandan MUMBAI, July 27 (Reuters) - Customer data from India's…
HSBC to hire 100 AI specialists, 100 wealth managers in boost to Singapore hub
HONG KONG, July 27 (Reuters) - HSBC will hire more than 100 artificial intelligence specialists…
